Subscribe
Tuesday, November 10, 2026
28.2 C
Bengaluru
type here...
Subscribe
Featured ArticleHealthcare News
2 min.Read

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

Anup Soans
By Anup Soans

https://www.pharmamanufacturing.com/articles/2011/095

A quiet but seismic shift is underway in global pharmaceuticals. Between 2025 and 2029, several blockbuster biologics — many of them cornerstones of cancer, autoimmune, and metabolic disease care — will go off patent.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

MedicinMan Market Intelligence

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

0
ChrysCapital’s acquisition of Novartis India and its transformation into...
MedicinMan Market Intelligence

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

0
Indian pharma is investing heavily in digital engagement. But...
MedicinMan Market Intelligence

Indian Pharma 2026: The Growth Engine Is Changing

0
The Indian Pharmaceutical Market isn't just growing. Its centre...
Healthcare C-Suite Movements

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

0
Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...
MedicinMan Market Intelligence

The paradox of the “Pharmacy of the World.” 💊

0
India has world-scale formulation capability, yet the chemistry beneath...

Topics

MedicinMan Market Intelligence

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

0
ChrysCapital’s acquisition of Novartis India and its transformation into...
MedicinMan Market Intelligence

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

0
Indian pharma is investing heavily in digital engagement. But...
MedicinMan Market Intelligence

Indian Pharma 2026: The Growth Engine Is Changing

0
The Indian Pharmaceutical Market isn't just growing. Its centre...
Healthcare C-Suite Movements

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

0
Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...
MedicinMan Market Intelligence

The paradox of the “Pharmacy of the World.” 💊

0
India has world-scale formulation capability, yet the chemistry beneath...
MedicinMan Market Intelligence

The Innovator’s Gene and the Generic’s Promise

0
A medicine must first be discovered. It must then...
MedicinMan Market Intelligence

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

0
Private capital is transforming India's healthcare landscape. But is...
Healthcare C-Suite Movements

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

0
Anuj Pasrija has been elevated to Country Lead, Johnson...
spot_img

Related Articles

spot_imgspot_img
Previous article
Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?
Next article
Careers in Medical Device Companies

MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More

Company

Headlines

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

0
ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

0
Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

0
The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

0
Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 | Crafted by SlamDunk